Estadísticas

 array:23 [
  "pii" => "S1578219018302269"
  "issn" => "15782190"
  "doi" => "10.1016/j.adengl.2018.06.015"
  "estado" => "S300"
  "fechaPublicacion" => "2018-09-01"
  "aid" => "1976"
  "copyrightAnyo" => "2018"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "fla"
  "cita" => "Actas Dermosifiliogr. 2018;109:617-23"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 6
    "formatos" => array:2 [
      "HTML" => 2
      "PDF" => 4
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:18 [
      "pii" => "S000173101830214X"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2018.04.004"
      "estado" => "S300"
      "fechaPublicacion" => "2018-09-01"
      "aid" => "1976"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "fla"
      "cita" => "Actas Dermosifiliogr. 2018;109:617-23"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 218
        "formatos" => array:2 [
          "HTML" => 139
          "PDF" => 79
        ]
      ]
      "es" => array:14 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">ORIGINAL</span>"
        "titulo" => "Descripci&#243;n de los pacientes que reciben biol&#243;gicos como primer tratamiento sist&#233;mico en el registro BIOBADADERM durante el periodo 2008-2016"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:3 [
          0 => "es"
          1 => "es"
          2 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "617"
            "paginaFinal" => "623"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 1
          "multimedia" => array:5 [
            "identificador" => "fig0010"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => false
            "mostrarDisplay" => true
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "fx1.jpeg"
                "Alto" => 465
                "Ancho" => 1333
                "Tamanyo" => 61396
              ]
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "G&#46; Carretero Hern&#225;ndez, C&#46; Ferr&#225;ndiz, R&#46; Rivera D&#237;az, E&#46; Daud&#233;n Tello, P&#46; de la Cueva-Dobao, F&#46;J&#46; G&#243;mez-Garc&#237;a, E&#46; Herrera-Ceballos, I&#46; Belinch&#243;n Romero, J&#46;L&#46; L&#243;pez-Estebaranz, M&#46; Alsina Gibert, J&#46;L&#46; S&#225;nchez-Carazo, M&#46; Ferr&#225;n Farr&#233;s, A&#46; Gonz&#225;lez Quesada, J&#46;M&#46; Carrascosa Carrillo, M&#46; Llamas-Velasco, M&#46;V&#46; Mendiola Fern&#225;ndez, D&#46; Ruiz Genao, C&#46; Mu&#241;oz Santos, I&#46; Garc&#237;a-Doval, M&#46;A&#46; Descalzo"
            "autores" => array:21 [
              0 => array:2 [
                "nombre" => "G&#46;"
                "apellidos" => "Carretero Hern&#225;ndez"
              ]
              1 => array:2 [
                "nombre" => "C&#46;"
                "apellidos" => "Ferr&#225;ndiz"
              ]
              2 => array:2 [
                "nombre" => "R&#46;"
                "apellidos" => "Rivera D&#237;az"
              ]
              3 => array:2 [
                "nombre" => "E&#46;"
                "apellidos" => "Daud&#233;n Tello"
              ]
              4 => array:2 [
                "nombre" => "P&#46;"
                "apellidos" => "de la Cueva-Dobao"
              ]
              5 => array:2 [
                "nombre" => "F&#46;J&#46;"
                "apellidos" => "G&#243;mez-Garc&#237;a"
              ]
              6 => array:2 [
                "nombre" => "E&#46;"
                "apellidos" => "Herrera-Ceballos"
              ]
              7 => array:2 [
                "nombre" => "I&#46;"
                "apellidos" => "Belinch&#243;n Romero"
              ]
              8 => array:2 [
                "nombre" => "J&#46;L&#46;"
                "apellidos" => "L&#243;pez-Estebaranz"
              ]
              9 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Alsina Gibert"
              ]
              10 => array:2 [
                "nombre" => "J&#46;L&#46;"
                "apellidos" => "S&#225;nchez-Carazo"
              ]
              11 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Ferr&#225;n Farr&#233;s"
              ]
              12 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Gonz&#225;lez Quesada"
              ]
              13 => array:2 [
                "nombre" => "J&#46;M&#46;"
                "apellidos" => "Carrascosa Carrillo"
              ]
              14 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Llamas-Velasco"
              ]
              15 => array:2 [
                "nombre" => "M&#46;V&#46;"
                "apellidos" => "Mendiola Fern&#225;ndez"
              ]
              16 => array:2 [
                "nombre" => "D&#46;"
                "apellidos" => "Ruiz Genao"
              ]
              17 => array:2 [
                "nombre" => "C&#46;"
                "apellidos" => "Mu&#241;oz Santos"
              ]
              18 => array:2 [
                "nombre" => "I&#46;"
                "apellidos" => "Garc&#237;a-Doval"
              ]
              19 => array:2 [
                "nombre" => "M&#46;A&#46;"
                "apellidos" => "Descalzo"
              ]
              20 => array:1 [
                "colaborador" => "grupo de estudio de Biobadaderm"
              ]
            ]
          ]
        ]
        "resumen" => array:1 [
          0 => array:3 [
            "titulo" => "Graphical abstract"
            "clase" => "graphical"
            "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0010"></elsevierMultimedia></p></span>"
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S1578219018302269"
          "doi" => "10.1016/j.adengl.2018.06.015"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018302269?idApp=UINPBA000044"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173101830214X?idApp=UINPBA000044"
      "url" => "/00017310/0000010900000007/v1_201809020415/S000173101830214X/v1_201809020415/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S1578219018302245"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2018.06.013"
    "estado" => "S300"
    "fechaPublicacion" => "2018-09-01"
    "aid" => "1957"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Actas Dermosifiliogr. 2018;109:624-30"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 127
      "formatos" => array:2 [
        "HTML" => 119
        "PDF" => 8
      ]
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">ORIGINAL</span>"
      "titulo" => "Practice Models in Teledermatology in Spain&#58; Longitudinal Study&#44; 2009-2014"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "624"
          "paginaFinal" => "630"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Modelos de pr&#225;ctica de la teledermatolog&#237;a en Espa&#241;a&#46; Estudio longitudinal 2009-2014"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1751
              "Ancho" => 2385
              "Tamanyo" => 284041
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Spanish centers that use teledermatology by autonomous community&#44; 2009 vs 2014 &#40;25 in 2009&#59; 70 in 2014&#41;&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "G&#46; Romero, D&#46; de Argila, L&#46; Ferrandiz, M&#46;P&#46; S&#225;nchez, S&#46; Va&#241;&#243;, R&#46; Taberner, P&#46; Pasquali, C&#46; de la Torre, F&#46; Alfageme, J&#46; Malvehy, D&#46; Moreno-Ram&#237;rez"
          "autores" => array:11 [
            0 => array:2 [
              "nombre" => "G&#46;"
              "apellidos" => "Romero"
            ]
            1 => array:2 [
              "nombre" => "D&#46;"
              "apellidos" => "de Argila"
            ]
            2 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Ferrandiz"
            ]
            3 => array:2 [
              "nombre" => "M&#46;P&#46;"
              "apellidos" => "S&#225;nchez"
            ]
            4 => array:2 [
              "nombre" => "S&#46;"
              "apellidos" => "Va&#241;&#243;"
            ]
            5 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "Taberner"
            ]
            6 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "Pasquali"
            ]
            7 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "de la Torre"
            ]
            8 => array:2 [
              "nombre" => "F&#46;"
              "apellidos" => "Alfageme"
            ]
            9 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Malvehy"
            ]
            10 => array:2 [
              "nombre" => "D&#46;"
              "apellidos" => "Moreno-Ram&#237;rez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0001731018301820"
        "doi" => "10.1016/j.ad.2018.03.015"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018301820?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018302245?idApp=UINPBA000044"
    "url" => "/15782190/0000010900000007/v1_201809020417/S1578219018302245/v1_201809020417/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S1578219018302129"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2018.06.003"
    "estado" => "S300"
    "fechaPublicacion" => "2018-09-01"
    "aid" => "1940"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Actas Dermosifiliogr. 2018;109:610-6"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 12
      "formatos" => array:2 [
        "HTML" => 6
        "PDF" => 6
      ]
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
      "titulo" => "The First Year of the AEVD Primary Cutaneous Lymphoma Registry"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "610"
          "paginaFinal" => "616"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Registro de linfomas cut&#225;neos primarios de la AEDV&#58; primer a&#241;o de funcionamiento"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 852
              "Ancho" => 1503
              "Tamanyo" => 96937
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Baseline evaluation of patients with primary cutaneous lymphoma&#46; MM&#47;SS indicates mycosis fungoides&#47;S&#233;zary syndrome&#59; CLPD&#44; cutaneous lymphoproliferative disorder&#59; OTCL&#44; other T-cell lymphoma&#59; CBCL&#44; cutaneous B-cell lymphoma&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Y&#46; Pe&#241;ate, O&#46; Servitje, S&#46; Machan, R&#46; Fern&#225;ndez-de-Misa, M&#46;T&#46; Estrach, E&#46; Acebo, J&#46; Mitxelena, M&#46;D&#46; Ram&#243;n, A&#46; Fl&#243;rez, M&#46; Blanes, M&#46; Morillo, S&#46; Medina, J&#46; Bassas, A&#46; Zayas, P&#46; Espinosa, A&#46; P&#233;rez, N&#46; G&#243;nzalez-Romero, J&#46;D&#46; Dom&#237;nguez, C&#46; Muniesa, J&#46; L&#243;pez Robles, A&#46; Combalia, I&#46; Yanguas, H&#46; Suh, I&#46; Polo-Rodr&#237;guez, I&#46; Bielsa, A&#46; Mateu, B&#46; Ferrer, M&#46;A&#46; Descalzo, I&#46; Garc&#237;a-Doval, P&#46;L&#46; Ortiz-Romero"
          "autores" => array:30 [
            0 => array:2 [
              "nombre" => "Y&#46;"
              "apellidos" => "Pe&#241;ate"
            ]
            1 => array:2 [
              "nombre" => "O&#46;"
              "apellidos" => "Servitje"
            ]
            2 => array:2 [
              "nombre" => "S&#46;"
              "apellidos" => "Machan"
            ]
            3 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "Fern&#225;ndez-de-Misa"
            ]
            4 => array:2 [
              "nombre" => "M&#46;T&#46;"
              "apellidos" => "Estrach"
            ]
            5 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "Acebo"
            ]
            6 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Mitxelena"
            ]
            7 => array:2 [
              "nombre" => "M&#46;D&#46;"
              "apellidos" => "Ram&#243;n"
            ]
            8 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Fl&#243;rez"
            ]
            9 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Blanes"
            ]
            10 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Morillo"
            ]
            11 => array:2 [
              "nombre" => "S&#46;"
              "apellidos" => "Medina"
            ]
            12 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Bassas"
            ]
            13 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Zayas"
            ]
            14 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "Espinosa"
            ]
            15 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "P&#233;rez"
            ]
            16 => array:2 [
              "nombre" => "N&#46;"
              "apellidos" => "G&#243;nzalez-Romero"
            ]
            17 => array:2 [
              "nombre" => "J&#46;D&#46;"
              "apellidos" => "Dom&#237;nguez"
            ]
            18 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Muniesa"
            ]
            19 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "L&#243;pez Robles"
            ]
            20 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Combalia"
            ]
            21 => array:2 [
              "nombre" => "I&#46;"
              "apellidos" => "Yanguas"
            ]
            22 => array:2 [
              "nombre" => "H&#46;"
              "apellidos" => "Suh"
            ]
            23 => array:2 [
              "nombre" => "I&#46;"
              "apellidos" => "Polo-Rodr&#237;guez"
            ]
            24 => array:2 [
              "nombre" => "I&#46;"
              "apellidos" => "Bielsa"
            ]
            25 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Mateu"
            ]
            26 => array:2 [
              "nombre" => "B&#46;"
              "apellidos" => "Ferrer"
            ]
            27 => array:2 [
              "nombre" => "M&#46;A&#46;"
              "apellidos" => "Descalzo"
            ]
            28 => array:2 [
              "nombre" => "I&#46;"
              "apellidos" => "Garc&#237;a-Doval"
            ]
            29 => array:2 [
              "nombre" => "P&#46;L&#46;"
              "apellidos" => "Ortiz-Romero"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0001731018301364"
        "doi" => "10.1016/j.ad.2018.03.006"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018301364?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018302129?idApp=UINPBA000044"
    "url" => "/15782190/0000010900000007/v1_201809020417/S1578219018302129/v1_201809020417/en/main.assets"
  ]
  "en" => array:20 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">ORIGINAL</span>"
    "titulo" => "Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "617"
        "paginaFinal" => "623"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "G&#46; Carretero Hern&#225;ndez, C&#46; Ferr&#225;ndiz, R&#46; Rivera D&#237;az, E&#46; Daud&#233;n Tello, P&#46; de la Cueva-Dobao, F&#46;J&#46; G&#243;mez-Garc&#237;a, E&#46; Herrera-Ceballos, I&#46; Belinch&#243;n Romero, J&#46;L&#46; L&#243;pez-Estebaranz, M&#46; Alsina Gibert, J&#46;L&#46; S&#225;nchez-Carazo, M&#46; Ferr&#225;n Farr&#233;s, A&#46; Gonz&#225;lez Quesada, J&#46;M&#46; Carrascosa Carrillo, M&#46; Llamas-Velasco, M&#46;V&#46; Mendiola Fern&#225;ndez, D&#46; Ruiz Genao, C&#46; Mu&#241;oz Santos, I&#46; Garc&#237;a-Doval, M&#46;A&#46; Descalzo"
        "autores" => array:21 [
          0 => array:3 [
            "nombre" => "G&#46;"
            "apellidos" => "Carretero Hern&#225;ndez"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "C&#46;"
            "apellidos" => "Ferr&#225;ndiz"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "R&#46;"
            "apellidos" => "Rivera D&#237;az"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "E&#46;"
            "apellidos" => "Daud&#233;n Tello"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "P&#46;"
            "apellidos" => "de la Cueva-Dobao"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "F&#46;J&#46;"
            "apellidos" => "G&#243;mez-Garc&#237;a"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "E&#46;"
            "apellidos" => "Herrera-Ceballos"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "I&#46;"
            "apellidos" => "Belinch&#243;n Romero"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "J&#46;L&#46;"
            "apellidos" => "L&#243;pez-Estebaranz"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "aff0050"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "M&#46;"
            "apellidos" => "Alsina Gibert"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">k</span>"
                "identificador" => "aff0055"
              ]
            ]
          ]
          10 => array:3 [
            "nombre" => "J&#46;L&#46;"
            "apellidos" => "S&#225;nchez-Carazo"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">l</span>"
                "identificador" => "aff0060"
              ]
            ]
          ]
          11 => array:3 [
            "nombre" => "M&#46;"
            "apellidos" => "Ferr&#225;n Farr&#233;s"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">m</span>"
                "identificador" => "aff0065"
              ]
            ]
          ]
          12 => array:4 [
            "nombre" => "A&#46;"
            "apellidos" => "Gonz&#225;lez Quesada"
            "email" => array:1 [
              0 => "ali&#95;gq&#64;hotmail&#46;com"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          13 => array:3 [
            "nombre" => "J&#46;M&#46;"
            "apellidos" => "Carrascosa Carrillo"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          14 => array:3 [
            "nombre" => "M&#46;"
            "apellidos" => "Llamas-Velasco"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          15 => array:3 [
            "nombre" => "M&#46;V&#46;"
            "apellidos" => "Mendiola Fern&#225;ndez"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
          16 => array:3 [
            "nombre" => "D&#46;"
            "apellidos" => "Ruiz Genao"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "aff0050"
              ]
            ]
          ]
          17 => array:3 [
            "nombre" => "C&#46;"
            "apellidos" => "Mu&#241;oz Santos"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">k</span>"
                "identificador" => "aff0055"
              ]
            ]
          ]
          18 => array:3 [
            "nombre" => "I&#46;"
            "apellidos" => "Garc&#237;a-Doval"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">n</span>"
                "identificador" => "aff0070"
              ]
            ]
          ]
          19 => array:3 [
            "nombre" => "M&#46;A&#46;"
            "apellidos" => "Descalzo"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">n</span>"
                "identificador" => "aff0070"
              ]
            ]
          ]
          20 => array:1 [
            "colaborador" => "grupo de estudio de Biobadaderm"
          ]
        ]
        "afiliaciones" => array:14 [
          0 => array:3 [
            "entidad" => "Hospital Universitario de Gran Canaria Dr&#46; Negr&#237;n&#44; Las Palmas de Gran Canaria&#44; Espa&#241;a"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Unidad de Investigaci&#243;n&#44; Fundaci&#243;n Piel Sana&#44; Academia Espa&#241;ola de Dermatolog&#237;a y Venereolog&#237;a&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Hospital Universitario Germans Trias i Pujol&#44; Universidad Aut&#243;noma de Barcelona&#44; Badalona&#44; Barcelona&#44; Espa&#241;a"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Hospital Universitario 12 de Octubre&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Hospital Universitario de La Princesa&#44; Instituto de Investigaci&#243;n Sanitaria La Princesa &#40;IIS-IP&#41;&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Hospital Infanta Leonor&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Hospital Universitario Reina Sof&#237;a&#44; C&#243;rdoba&#44; Espa&#241;a"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
          7 => array:3 [
            "entidad" => "Hospital Universitario Virgen de la Victoria&#44; M&#225;laga&#44; Espa&#241;a"
            "etiqueta" => "h"
            "identificador" => "aff0040"
          ]
          8 => array:3 [
            "entidad" => "Hospital General Universitario de Alicante&#44; Instituto de Investigaci&#243;n Sanitaria y Biom&#233;dica de Alicante &#40;ISABIAL&#41;&#44; Alicante&#44; Espa&#241;a"
            "etiqueta" => "i"
            "identificador" => "aff0045"
          ]
          9 => array:3 [
            "entidad" => "Hospital Universitario Fundaci&#243;n Alcorc&#243;n&#44; Alcorc&#243;n&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "j"
            "identificador" => "aff0050"
          ]
          10 => array:3 [
            "entidad" => "Hospital Cl&#237;nic de Barcelona&#44; Universitat de Barcelona&#44; Barcelona&#44; Espa&#241;a"
            "etiqueta" => "k"
            "identificador" => "aff0055"
          ]
          11 => array:3 [
            "entidad" => "Hospital General Universitario de Valencia&#44; Valencia&#44; Espa&#241;a"
            "etiqueta" => "l"
            "identificador" => "aff0060"
          ]
          12 => array:3 [
            "entidad" => "Hospital del Mar&#44; Parc de Salut Mar&#44; Barcelona&#44; Espa&#241;a"
            "etiqueta" => "m"
            "identificador" => "aff0065"
          ]
          13 => array:3 [
            "entidad" => "Hospital General de Granollers&#44; Granollers&#44; Barcelona&#44; Espa&#241;a"
            "etiqueta" => "n"
            "identificador" => "aff0070"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Descripci&#243;n de los pacientes que reciben biol&#243;gicos como primer tratamiento sist&#233;mico en el registro BIOBADADERM durante el periodo 2008-2016"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 3198
            "Ancho" => 1500
            "Tamanyo" => 203790
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Withdrawal from treatment&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Psoriasis is a chronic disease that affects 2&#46;3&#37; of the Spanish population&#46;<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">1</span></a> Although the percentage of patients with severe forms is unknown&#44; it is estimated to be 20&#46;3&#37; for psoriasis and 25&#46;7&#37; for psoriatic arthritis&#46;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">2</span></a> Some patients are undertreated&#44;<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">3</span></a> and it is estimated that in Spain&#44; only 6&#46;8&#37; receive systemic therapy&#46;<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">4</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The biologic drugs approved for treatment of psoriasis are etanercept&#44; infliximab&#44; adalimumab&#44; ustekinumab&#44; secukinumab&#44; and ixekizumab&#46; According to their summaries of product characteristics&#44; these drugs are usually indicated as second-line agents in patients who have not responded to other treatments&#46; However&#44; they can be used as first-line treatment in specific clinical situations or at the physician&#39;s discretion&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">The main objective of the present study&#44; therefore&#44; was to compare the demographic&#44; clinical&#44; and safety profiles of patients who received biologic treatment as a first-line option &#40;na&#239;ve&#41; with those of patients who received biologics as second-line therapy&#46; We based our study on data from the Spanish Registry of Adverse Events Associated With Biologic Drugs in Dermatology &#40;Registro Espa&#241;ol de Acontecimientos Adversos Asociados con Medicamentos Biol&#243;gicos en Dermatolog&#237;a &#91;BIOBADADERM&#93;&#41;&#44; which&#44; since 2008&#44; has prospectively included patients with moderate to severe psoriasis who are receiving systemic therapy with biologic and nonbiologic drugs&#46; Complete information on the cohort can be found on the BIOBADERM webpage &#40;<a id="intr0010" class="elsevierStyleInterRef" href="https://biobadaderm.fundacionpielsana.es/">https&#58;&#47;&#47;biobadaderm&#46;fundacionpielsana&#46;es&#47;</a>&#41;&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Material and Methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Study design&#46; Study population and comparison groups</span><p id="par0020" class="elsevierStylePara elsevierViewall">The study population comprised patients included in the BIOBADADERM registry between January 2008 and November 2016&#46; We divided this population into 2 cohorts&#58; &#40;<span class="elsevierStyleItalic">a</span>&#41; a treatment-na&#239;ve cohort&#44; ie&#44; patients receiving a biologic as first-line therapy &#40;etanercept&#44; infliximab&#44; adalimumab&#44; ustekinumab&#44; and secukinumab&#8212;ixekizumab had not been approved when the study closed&#41;&#59; and &#40;<span class="elsevierStyleItalic">b</span>&#41; a conventionally treated cohort&#44; ie&#44; patients who had previously received conventional systemic treatment &#40;acitretin&#44; ciclosporin&#44; methotrexate&#41;&#59; apremilast was not included&#44; as it had not been approved at the time&#46; Phototherapy was not considered systemic treatment&#46; Patient data included sex&#44; age&#44; time since onset&#44; baseline Psoriasis Area and Severity Index &#40;PASI&#41;&#44; type of psoriasis&#44; associated comorbid conditions&#44; treatment used&#44; reason for suspension&#44; follow-up time&#44; and adverse events&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Statistical Analysis</span><p id="par0025" class="elsevierStylePara elsevierViewall">Demographic and descriptive data are expressed as whole numbers and percentages in the case of categorical variables and as mean &#40;SD&#41; in the case of continuous quantitative variables&#46; A descriptive analysis of the variables in each group was performed using the &#967;<span class="elsevierStyleSup">2</span> test and <span class="elsevierStyleItalic">t</span> test&#46; The cumulative incidence of the reasons for suspension of therapy &#40;inefficacy&#44; adverse events&#44; and remission&#41; was presented graphically as an estimation of the probability of suspending treatment&#46; Each of the reasons was considered to be a competitive risk for the others&#46; The incidence rates of the adverse events &#40;per 1000 person-years&#41; were also estimated&#44; with their 95&#37; confidence interval &#40;CI&#41;&#46; The rates in each group were then compared using the incidence rate ratio&#44; with its corresponding 95&#37; CI&#46;</p></span></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Results</span><p id="par0030" class="elsevierStylePara elsevierViewall">The series comprised 915 patients receiving a biologic drug&#58; 181 patients received a biologic as their first-line treatment and 734 after their treatment with a conventional agent failed&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">Women accounted for 39&#37; of treatment-na&#239;ve patients&#46; The mean &#40;SD&#41; PASI score was 15 &#40;9&#46;9&#41;&#44; and the mean &#40;SD&#41; time since onset of the disease before initiation of the biologic was 18 &#40;13&#41; years&#44; with no differences between the treatment-na&#239;ve group and the group treated with conventional therapy&#46; Mean &#40;SD&#41; age at the initiation of biologic therapy was significantly higher in the treatment-na&#239;ve cohort &#40;54 &#91;15&#93; years&#41; than in the cohort treated with conventional therapy &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>&#46;01&#41;&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> presents clinical data&#44; such as type of psoriasis&#44; and presence of psoriatic arthritis&#44; for which no significant differences were observed&#44; and associated comorbidities &#40;arterial hypertension&#44; diabetes&#44; chronic liver disease&#44; hepatitis C&#44; and HIV infection&#41;&#44; for which a statistically significantly greater presence was observed in the treatment cohort&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0045" class="elsevierStylePara elsevierViewall">The drugs received by both groups are shown in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#44; as is the percentage of patients who also received systemic treatment&#46; No statistically significant differences were observed between the 2 groups for any of the drugs&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0050" class="elsevierStylePara elsevierViewall">Mean follow-up time for biologics in the treatment-na&#239;ve cohort was 2&#46;58 years&#44; which did not differ from that of the conventionally treated cohort &#40;2&#46;38 years&#41; &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#46;41&#41;&#46;</p><p id="par0055" class="elsevierStylePara elsevierViewall">Of the 181 patients in the treatment-na&#239;ve cohort&#44; 68&#46;5&#37; had stopped treatment at some time during the study&#46; The reasons are shown in <a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>&#46; No significant differences were found between the cohorts &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#46;19&#41;&#46; However&#44; the cumulative incidence of withdrawal of treatment due to remission was greater in the cohort that received conventional treatment &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#46;01&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>A-C&#41;&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0060" class="elsevierStylePara elsevierViewall">Patients in the treatment-na&#239;ve cohort presented a total of 310 adverse events &#40;467 patient-years&#41;&#44; of which 278 were mild&#44; 30 severe&#44; and 2 fatal &#40;pancreatic adenocarcinoma and carcinoid tumor of the cecum&#41;&#46; The overall adverse event rate &#40;per 1000 patient-years&#41; in the treatment-naive cohort was 763&#46;5 &#40;95&#37; CI&#44; 593&#46;6-741&#46;7&#41;&#44; and there were no significant differences with respect to the patients who received conventional treatment &#40;incidence rate ratio&#44; 1&#46;12&#59; 95&#37; CI&#44; 0&#46;99-1&#46;27&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#46;084&#41; &#40;<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Discussion</span><p id="par0065" class="elsevierStylePara elsevierViewall">Most published data on the efficacy and safety of biologics in psoriasis refer to their use as second-line treatment in patients with moderate to severe disease&#46; Nevertheless&#44; the guidelines of the psoriasis group of the Spanish Academy of Dermatology also include an indication for the use of these drugs in other situations &#40;<a class="elsevierStyleCrossRef" href="#tbl0025">Table 5</a>&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">5</span></a> Therefore&#44; data from a biologic-na&#239;ve cohort would be of interest when investigating these aspects&#46;</p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia><p id="par0070" class="elsevierStylePara elsevierViewall">The present study included 915 patients from BIOBADADERM&#44; of whom 181 &#40;19&#46;78&#37;&#41; were treatment-na&#239;ve&#46;</p><p id="par0075" class="elsevierStylePara elsevierViewall">While the profile of both cohorts is very similar&#44; na&#239;ve patients receive treatment at an older age &#40;54 vs 50 years&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#46;003&#41;&#46; However&#44; this finding is not explained by the degree of severity &#40;PASI na&#239;ve 15 vs PASI conventional 15&#46;1&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#46;91&#41; or by the time since diagnosis &#40;na&#239;ve 18 years vs conventional 19 years&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#46;33&#41;&#46; Despite the initial caution with respect to the use of biologics in elderly persons&#44; our group had previously confirmed the growing tendency to use these drugs in this population&#46;<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">6</span></a> Furthermore&#44; it is noteworthy that in both cohorts&#44; patients had to wait a mean of 18 years before receiving systemic treatment &#40;biologics or systemic&#41;&#44; although it is unknown whether these data are similar in other series&#46;</p><p id="par0080" class="elsevierStylePara elsevierViewall">Occasionally&#44; the indication for a conventional drug is hampered by the presence of comorbid conditions&#46; In fact&#44; in this study&#44; we observed that treatment-na&#239;ve patients more frequently had arterial hypertension &#40;31&#37; vs 17&#37;&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>&#46;01&#41;&#44; diabetes &#40;23&#37; vs 10&#37;&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>&#46;01&#41;&#44; chronic liver disease &#40;12&#37; vs 5&#37;&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>&#46;01&#41;&#44; and hepatitis C &#40;6&#37; vs 2&#37;&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#46;015&#41;&#46; The difference is also significant with respect to the presence of HIV infection &#40;2&#37; vs 1&#37;&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>&#46;01&#41;&#44; although we cannot confirm that these were the direct reasons for prescription of the initial biologic&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">The distribution of the biologics used is similar&#46; Consistent with other published series&#44;<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">7&#8211;9</span></a> etanercept was the most frequently used drug in both groups&#44; followed by adalimumab&#44; ustekinumab&#44; and infliximab&#46; Therefore&#44; it seems that the prescriber&#39;s criteria do not differ when choosing drugs for first- or second-line treatment&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">The percentage of cases in which a systemic drug was added was comparable &#40;14&#37; vs 20&#37;&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#46;08&#41;&#46; Similarly&#44; no differences were recorded with respect to mean follow-up time &#40;2&#46;58 vs 2&#46;41 years&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#46;41&#41;&#46; Therefore&#44; the data show that patients were managed using the same clinical criteria&#46;</p><p id="par0095" class="elsevierStylePara elsevierViewall">The reasons for withdrawal of the drug in both cohorts were similar with respect to overall percentages &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#46;19&#41;&#46; However&#44; in terms of cumulative incidence&#44; suspension due to remission was significantly less frequent in the treatment-na&#239;ve cohort than in the conventional cohort &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#46;01&#41;&#46; This observation cannot be explained by differences in severity or in clinical management&#59; therefore&#44; if no confounders are identified&#44; then disease control may differ depending on whether the drugs are used as first- or second-line treatment&#46;</p><p id="par0100" class="elsevierStylePara elsevierViewall">The overall rate &#40;per 1000 person-years&#41; of adverse events in the treatment-na&#239;ve cohort was slightly higher than in the cohort that received conventional treatment&#44; although the differences were not significant &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#46;08&#41;&#46; Similarly&#44; no differences were observed between the 2 cohorts when the rates of adverse events were analyzed separately&#46; A total of 3 fatal adverse events were recorded &#40;2 in the na&#239;ve cohort and 1 in the conventional cohort&#41; &#40;<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>&#41;&#46; The time when a biologic is prescribed does not seem to modify its adverse effects&#44; and the drugs can be considered equally safe&#46;</p><p id="par0105" class="elsevierStylePara elsevierViewall">Undoubtedly&#44; the use of a biologic as first-line systemic treatment raises interesting questions&#58; Does the indication of the biologic as a first-line treatment modify the course of the disease&#63; Does it lead to faster and more intense clearance&#63; Can it control the potential comorbid conditions associated with the disease&#44; especially bone and joint degeneration in patients with arthritis&#63; Will the same safety data be recorded regardless of whether the drug is used as first-line or second-line treatment&#63;</p><p id="par0110" class="elsevierStylePara elsevierViewall">These questions lead us to hypothesize that early treatment of psoriasis could modify the natural course and treatment of the disease and to ask whether there would be any difference between starting with a conventional drug and starting directly with a biologic&#46; In this respect&#44; data on rheumatoid arthritis support the notion that use of a biologic as first-line therapy could modify inflammatory activity and severity&#44;<a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">10&#8211;12</span></a> although we do not yet have data for psoriasis&#46; In any case&#44; the clinical scenario is not comparable&#44; since rheumatoid arthritis can have a chronic degenerative course&#44; which is typical of psoriatic arthritis&#44; but not of psoriasis&#46;</p><p id="par0115" class="elsevierStylePara elsevierViewall">In clinical practice&#44; patients often switch from one drug to another because of a lack of response or because of adverse events or comorbidities that require therapy to be modified&#46; On the other hand&#44; long-term use of these agents shows them to be safe&#44;<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">13</span></a> and&#44; taking into account the fact that a larger percentage of biologics reach optimal therapeutic objectives than conventional drugs&#44; we must ask why we should not start treatment with a biologic&#46; Aside from cost and indication&#44; we require more data on the efficacy and safety of biologics as first-line therapy in order to address this question appropriately&#46;</p><p id="par0120" class="elsevierStylePara elsevierViewall">One of the strengths of the present study is that it brings together data from a large cohort of patients who had not previously received biologic drugs &#40;181&#41; and who were continuously and homogeneously followed according to usual clinical practice at 13 different centers&#46; The main limitation&#44; however&#44; is that the indication for each individual patient is not random&#44; but is chosen based on the criteria of the prescribing physician&#46; Consequently&#44; the decision may be influenced by characteristics such as age&#44; comorbid conditions&#44; availability of drugs at a specific center&#44; experience&#44; and other unknown factors that could generate confounders&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">The study is also limited by the fact that efficacy data are poor&#44; since only indirect measures are available&#44; such as the reason for suspension or the duration of treatment&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Conclusions</span><p id="par0130" class="elsevierStylePara elsevierViewall">Patients from both groups were generally very similar&#44; although the percentage of comorbid conditions and age at onset were higher in treatment-na&#239;ve patients&#46; One possible explanation would be that the biologic is chosen to prevent adverse effects or interactions with comorbid conditions&#46;</p><p id="par0135" class="elsevierStylePara elsevierViewall">The fact that no differences were found between the groups with respect to the reasons for suspension and safety reinforces the safety of biologics in this context&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Conflicts of Interest</span><p id="par0140" class="elsevierStylePara elsevierViewall">Dr&#46; G&#46; Carretero Hern&#225;ndez has acted as a consultant&#44; speaker&#44; and&#47;or clinical trial investigator for AbbVie&#44; Janssen-Cilag&#44; Pfizer&#44; MSD&#44; Celgene&#44; Novartis&#44; Almirall S&#46;A&#46;&#44; and Leo-Pharma&#46; Dr&#46; C&#46; Ferr&#225;ndiz has acted as a consultant&#44; speaker&#44; and&#47;or clinical trial investigator for AbbVie&#44; Janssen Pharmaceuticals Inc&#46;&#44; Pfizer&#44; Celgene&#44; Lilly&#44; and Almirall S&#46;A&#46; and has received grant support from AbbVie&#46; Dr&#46; R&#46; Rivera D&#237;az has acted as a consultant for AbbVie Laboratories&#44; Janssen Pharmaceuticals Inc&#46;&#44; MSD&#44; and Pfizer-Wyeth&#46; Dr&#46; E&#46; Daud&#233;n Tello as acted as a consultant for AbbVie Laboratories&#44; Amgen&#44; Astellas&#44; Celgene&#44; Centocor Ortho Biotech Inc&#46;&#44; Galderma&#44; Glaxo&#44; Janssen-Cilag&#44; Leo-Pharma&#44; MSD&#44; Novartis&#44; and Pfizer Inc&#46; and has received remuneration from Abbott Laboratories&#44; Amgen&#44; Celgene&#44; Janssen-Cilag Pty Ltd&#46;&#44; Leo-Pharma&#44; MSD&#44; Novartis&#44; and Pfizer Inc&#46; He has also acted as a speaker for AbbVie Laboratories&#44; Janssen Pharmaceuticals Inc&#46;&#44; MSD&#44; and Pfizer Inc&#46; and has received grant support from AbbVie Laboratories&#44; Janssen Pharmaceuticals Inc&#46;&#44; and Pfizer Inc&#46; Dr&#46; P&#46; de la Cueva-Dobao has acted as a consultant for Janssen-Cilag&#44; AbbVie&#44; MSD&#44; Pfizer&#44; and Leo-Pharma&#46; Dr&#46; E&#46; Herrera-Ceballos has acted as a consultant and speaker for AbbVie Laboratories&#44; Janssen Pharmaceuticals Inc&#46;&#44; and Pfizer-Wyeth&#46; Dr&#46; I&#46; Belinch&#243;n Romero has acted as a consultant for Pfizer-Wyeth&#44; Janssen Pharmaceuticals Inc&#46;&#44; MSD&#44; Almirall S&#46;A&#46;&#44; Lilly&#44; and Leo-Pharma and as a speaker for AbbVie&#44; Pfizer-Wyeth&#44; Janssen Pharmaceuticals Inc&#46;&#44; Novartis&#44; and MSD&#46; Dr&#46; J&#46;L&#46; L&#243;pez-Estebaranz has acted as a consultant for Abbott Laboratories&#44; Janssen Pharmaceuticals Inc&#46;&#44; MSD&#44; and Pfizer-Wyeth and as a speaker for AbbVie Laboratories&#44; Janssen Pharmaceuticals Inc&#46;&#44; MSD&#44; and Pfizer-Wyeth&#46; Dr&#46; M&#46; Alsina Gibert has acted as a consultant for AbbVie Laboratories and Merck&#47;Schering-Plough&#46; Dr&#46; J&#46;L&#46; S&#225;nchez-Carazo has acted as a consultant for AbbVie Laboratories&#44; Janssen Pharmaceuticals Inc&#46;&#44; MSD&#44; and Pfizer-Wyeth&#46; Dr&#46; M&#46; Ferr&#225;n Farr&#233;s has acted as a consultant for MSD&#44; Pfizer&#44; AbbVie&#44; and Janssen and as a speaker for MSD&#44; AbbVie&#44; and Janssen&#46; She has also worked as a researcher for MSD&#44; AbbVie&#44; Pfizer&#44; and Janssen&#46; Dr&#46; J&#46;M&#46; Carrascosa Carrillo has acted as a consultant and speaker for AbbVie Laboratories&#44; Janssen Pharmaceuticals Inc&#46;&#44; MSD&#44; Pfizer-Wyeth&#44; Novartis&#44; and Celgene&#46; Dr&#46; M&#46; Llamas Velasco has received financial support for participating in conferences from AbbVie&#44; Janssen&#44; and Novartis and has acted as a speaker for AbbVie and Novartis&#46; Dr&#46; D&#46; Ruiz Genao has received financial support for participating in conferences from Pfizer&#44; AbbVie&#44; Janssen&#44; and Novartis and has acted as a speaker for AbbVie&#44; Pfizer&#44; Janssen&#44; and Novartis&#46; Dr&#46; I&#46; Garc&#237;a-Doval has received financial support for participating in conferences from Merck&#47;Schering-Plough&#44; Pfizer&#44; and Janssen&#46; The remaining authors declare that they have no conflicts of interest&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:11 [
        0 => array:3 [
          "identificador" => "xres1077280"
          "titulo" => "Abstract"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0005"
              "titulo" => "Introduction and objectives"
            ]
            1 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Material and method"
            ]
            2 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "Results"
            ]
            3 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Conclusions"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1023306"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres1077279"
          "titulo" => "Resumen"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0025"
              "titulo" => "Introducci&#243;n y objetivos"
            ]
            1 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "Material y m&#233;todo"
            ]
            2 => array:2 [
              "identificador" => "abst0035"
              "titulo" => "Resultados"
            ]
            3 => array:2 [
              "identificador" => "abst0040"
              "titulo" => "Conclusiones"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec1023307"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Material and Methods"
          "secciones" => array:2 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Study design&#46; Study population and comparison groups"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Statistical Analysis"
            ]
          ]
        ]
        6 => array:2 [
          "identificador" => "sec0025"
          "titulo" => "Results"
        ]
        7 => array:2 [
          "identificador" => "sec0030"
          "titulo" => "Discussion"
        ]
        8 => array:2 [
          "identificador" => "sec0035"
          "titulo" => "Conclusions"
        ]
        9 => array:2 [
          "identificador" => "sec0040"
          "titulo" => "Conflicts of Interest"
        ]
        10 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2017-07-10"
    "fechaAceptado" => "2018-04-15"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1023306"
          "palabras" => array:4 [
            0 => "Psoriasis"
            1 => "Psoriasis treatment"
            2 => "Biology therapy"
            3 => "Biologics for psoriasis"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1023307"
          "palabras" => array:4 [
            0 => "Psoriasis"
            1 => "Tratamiento para la psoriasis"
            2 => "Terapia biol&#243;gica"
            3 => "Biol&#243;gico antipsori&#225;sico"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Introduction and objectives</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Biologic drugs are usually prescribed as second-line treatment for psoriasis&#44; that is&#44; after the patient has first been treated with a conventional psoriasis drug&#46; There are&#44; however&#44; cases where&#44; depending on the characteristics of the patient or the judgement of the physician&#44; biologics may be chosen as first-line therapy&#46; No studies to date have analyzed the demographics or clinical characteristics of patients in this setting or the safety profile of the agents used&#46; The main aim of this study was to characterize these aspects of first-line biologic therapy and compare them to those observed for patients receiving biologics as second-line therapy&#46;</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Material and method</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">We conducted an observational study of 181 patients treated in various centers with a systemic biologic drug as first-line treatment for moderate to severe psoriasis between January 2008 and November 2016&#46; All the patients were registered in the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">The characteristics of the first- and second-line groups were very similar&#44; although the patients receiving a biologic as first-line treatment for their psoriasis were older&#46; No differences were observed for disease severity &#40;assessed using the PASI&#41; or time to diagnosis&#46; Hypertension&#44; diabetes&#44; and liver disease were all more common in the first-line group&#46; There were no differences between the groups in terms of reasons for drug withdrawal or occurrence of adverse effects&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">No major differences were found between patients with psoriasis receiving biologic drugs as first- or second-line therapy&#44; a finding that provides further evidence of the safety of biologic therapy in patients with psoriasis&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Introduction and objectives"
          ]
          1 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Material and method"
          ]
          2 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "Results"
          ]
          3 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Conclusions"
          ]
        ]
      ]
      "es" => array:3 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Introducci&#243;n y objetivos</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">La utilizaci&#243;n cl&#237;nica habitual de los f&#225;rmacos biol&#243;gicos en el tratamiento de la psoriasis es en segunda l&#237;nea&#44; es decir&#44; tras el uso previo de un f&#225;rmaco cl&#225;sico&#46; Sin embargo&#44; en casos particulares &#8211;particularidades del paciente o criterio m&#233;dico&#8211; se realiza la indicaci&#243;n en primera l&#237;nea&#46; No existen estudios sobre las caracter&#237;sticas demogr&#225;ficas&#44; cl&#237;nicas y de seguridad de los pacientes que reciben f&#225;rmaco biol&#243;gico en primera l&#237;nea&#46; Como objetivo primario se pretende determinar dichas caracter&#237;sticas de acuerdo con la iniciaci&#243;n de la terapia biol&#243;gica en primera o segunda l&#237;nea&#46;</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Material y m&#233;todo</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Se realiz&#243; un estudio descriptivo&#44; multic&#233;ntrico&#44; de 181 pacientes que iniciaron tratamiento biol&#243;gico como primer f&#225;rmaco sist&#233;mico para control de su psoriasis moderada-grave&#44; y que forman parte del Registro Espa&#241;ol de Acontecimientos Adversos Asociados con Medicamentos Biol&#243;gicos en Dermatolog&#237;a&#44; entre enero de 2008 y noviembre de 2016&#46;</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Los pacientes de ambos grupos son muy similares&#44; si bien se evidencia que el grupo que recibe el biol&#243;gico en primera l&#237;nea presenta una edad m&#225;s avanzada&#44; sin que se justifique por gravedad de la enfermedad &#40;PASI&#41; ni por el tiempo de evoluci&#243;n de esta desde el diagn&#243;stico&#46; En este grupo de pacientes es m&#225;s frecuente la presencia de hipertensi&#243;n&#44; diabetes y hepatopat&#237;a&#46; No hemos encontrado diferencias en motivos de suspensi&#243;n ni seguridad entre ambos grupos&#46;</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">No se han encontrado diferencias relevantes entre los 2 grupos&#44; lo cual refuerza la seguridad de los f&#225;rmacos biol&#243;gicos en este contexto&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0025"
            "titulo" => "Introducci&#243;n y objetivos"
          ]
          1 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "Material y m&#233;todo"
          ]
          2 => array:2 [
            "identificador" => "abst0035"
            "titulo" => "Resultados"
          ]
          3 => array:2 [
            "identificador" => "abst0040"
            "titulo" => "Conclusiones"
          ]
        ]
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Please cite this article as&#58; Hern&#225;ndez GC&#44; Ferr&#225;ndiz C&#44; D&#237;az RR&#44; Tello ED&#44; de la Cueva-Dobao P&#44; G&#243;mez-Garc&#237;a FJ&#44; et al&#46; Descripci&#243;n de los pacientes que reciben biol&#243;gicos como primer tratamiento sist&#233;mico en el registro BIOBADADERM durante el periodo 2008-2016&#46; Actas Dermosifiliogr&#46; 2018&#59;109&#58;617&#8211;623&#46;</p>"
      ]
    ]
    "multimedia" => array:6 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 3198
            "Ancho" => 1500
            "Tamanyo" => 203790
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Withdrawal from treatment&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Abbreviation&#58; COPD&#44; chronic obstructive pulmonary disease&#59; PASI&#44; Psoriasis Area and Severity Index&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">First-Line Biologics &#40;Na&#239;ve&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Second-Line Biologics&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span> Value&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleItalic">Demographic data</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Patients&#44; No&#46; &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">181 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">734 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Women&#44; No&#46; &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">71 &#40;39&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">277 &#40;38&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;72&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Mean &#40;SD&#41; age&#44; y&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">54 &#40;15&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">50 &#40;14&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;<span class="elsevierStyleHsp" style=""></span>&#46;01&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Mean &#40;SD&#41; time with disease at initiation of treatment&#44; y&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">18 &#40;13&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">19 &#40;12&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;33&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Mean &#40;SD&#41; PASI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">15 &#40;9&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">15&#46;1 &#40;9&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;91&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleItalic">Diagnosis&#44; No&#46; &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Plaque psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">172 &#40;95&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">703 &#40;96&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;66&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Guttate psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">9 &#40;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30 &#40;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Erythroderma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3 &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">22 &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;45&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Pustular psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1 &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12 &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;48&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Psoriasis palmaris et plantaris&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3 &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8 &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;46&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Psoriasis annularis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0 &#40;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5 &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;59&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Psoriatic arthritis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">26 &#40;14&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">151 &#40;21&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;06&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="4" align="left" valign="top"><span class="elsevierStyleItalic">Comorbidities&#44; No&#46; &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Ischemic heart disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">7 &#40;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12 &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Heart failure&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2 &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4 &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;49&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Arterial hypertension&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">56 &#40;31&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">124 &#40;17&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;<span class="elsevierStyleHsp" style=""></span>&#46;01&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Diabetes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">41 &#40;23&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">73 &#40;10&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;<span class="elsevierStyleHsp" style=""></span>&#46;01&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Hypercholesterolemia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">50 &#40;28&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">167 &#40;23&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;37&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Cancer during the previous 5 y&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2 &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12 &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;83&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Chronic liver disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">22 &#40;12&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">40 &#40;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;<span class="elsevierStyleHsp" style=""></span>&#46;01&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Chronic kidney failure&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5 &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">11 &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;51&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>COPD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6 &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">16 &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;56&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Hepatitis B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">7 &#40;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">26 &#40;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;97&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Hepatitis C&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">11 &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">13 &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;01&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>HIV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0 &#40;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5 &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;<span class="elsevierStyleHsp" style=""></span>&#46;01&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1838869.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Patients&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Current Treatment&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">First-Line Biologic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Second-Line Biologic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span> Value&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Treatment with coadministration of other systemic drugs&#44; No&#46; &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">25 &#40;14&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">146 &#40;20&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;06&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Current treatment&#44; No&#46; &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;08&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Etanercept&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">77 &#40;43&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">290 &#40;40&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Infliximab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12 &#40;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">68 &#40;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Adalimumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">53 &#40;29&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">264 &#40;36&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Ustekinumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">39 &#40;22&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">112 &#40;15&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1838870.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Treatment&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Reason&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">First-Line Biologic &#40;Na&#239;ve&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Second-Line Biologic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span> Value&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Reason for suspension&#44; No&#46; &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">124 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">550 &#40;100&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#46;19&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Inefficacy or loss of effectiveness&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">51 &#40;41&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">217 &#40;39&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Adverse event&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">21 &#40;17&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">75 &#40;14&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Pregnancy or desire to become pregnant&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4 &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">13 &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Loss to follow-up&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">9 &#40;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">38 &#40;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Remission&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">17 &#40;14&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">130 &#40;24&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Other&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">22 &#40;18&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">77 &#40;14&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1838872.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Reasons for Suspension of Treatment&#46;</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Table 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Abbreviation&#58; AE&#44; adverse event&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">First-Line Biologic &#40;Na&#239;ve&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Second-Line Biologic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " colspan="5" align="left" valign="top"><span class="elsevierStyleItalic">Frequency&#44; No&#46; &#40;Patient-Years&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>All AEs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">310 &#40;467&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1052 &#40;1772&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Severe AEs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30 &#40;467&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">88 &#40;1772&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Nonsevere AEs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">278 &#40;467&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">963 &#40;1772&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Fatal AEs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2 &#40;467&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1 &#40;1772&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Incidence Rate &#40;95&#37; CI&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">P Value</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="5" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="5" align="left" valign="top"><span class="elsevierStyleItalic">Gross Rate &#40;per 1000 Person-Years&#41; &#40;95&#37; CI&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>All AEs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">763&#46;5 &#40;593&#46;6-741&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">593&#46;6 &#40;558&#46;8-630&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#46;12 &#40;0&#46;99-1&#46;27&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;08&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Severe AEs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">64&#46;2 &#40;44&#46;9-91&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">49&#46;7 &#40;40&#46;3-61&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#46;29 &#40;0&#46;85-1&#46;96&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;22&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Nonsevere AEs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">595&#46;0 &#40;529&#46;1-669&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">543&#46;4 &#40;510&#46;1-578&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#46;10 &#40;0&#46;96-1&#46;25&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;18&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Fatal AEs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&#46;3 &#40;1&#46;1-17&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;6 &#40;0&#46;1-4&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">7&#46;59 &#40;0&#46;69-83&#46;69&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;09&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1838871.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Adverse Events&#46;</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0025"
        "etiqueta" => "Table 5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at5"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; BSA&#44; body surface area&#59; DLQI&#44; Dermatology Life Quality Index&#59; PASI&#44; Psoriasis Area and Severity Index&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">A&#46; Systemic treatment &#40;conventional drugs or biologics&#41;&#58; indicated in patients with moderate to severe psoriasis&#44; that is&#44; who fulfill any of the following conditions&#58;</span><br><span class="elsevierStyleHsp" style=""></span>Not controlled with topical treatment<br><span class="elsevierStyleHsp" style=""></span>Extensive disease &#40;BSA<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>5-10&#37;&#41;&#44; PASI<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>10<br><span class="elsevierStyleHsp" style=""></span>Rapid deterioration<br><span class="elsevierStyleHsp" style=""></span>Visible areas compromised<br><span class="elsevierStyleHsp" style=""></span>Functional limitation &#40;palms and soles&#44; genitals&#41;<br><span class="elsevierStyleHsp" style=""></span>Perceived subjective severity &#40;DLQI<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#41;<br><span class="elsevierStyleHsp" style=""></span>Extensive pustular psoriasis or erythroderma<br><span class="elsevierStyleHsp" style=""></span>Association with psoriatic joint disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">B&#46; Biologic treatment&#58; according to the summaries of product characteristics&#44; biologics are currently indicated for treatment of patients with moderate to severe psoriasis who did not respond&#44; have a contraindication&#44; or present intolerance&#44; adverse effects&#44; or probable toxicity &#40;acute or because of a cumulative dose&#41; to conventional systemic treatment&#44; including acitretin&#44; methotrexate&#44; ciclosporin&#44; phototherapy or photo&#40;chemo&#41;therapy&#44; or to other biologic treatments and are included in this definition&#58;</span><br><span class="elsevierStyleHsp" style=""></span>Patients whose condition is not controlled effectively with available systemic agents &#40;alone or in combination&#41;<br><span class="elsevierStyleHsp" style=""></span>Patients with rapid relapses &#40;less than 3 months&#41; after stopping any type of treatment<br><span class="elsevierStyleHsp" style=""></span>Patients who require high doses of conventional systemic treatment &#40;with risk of adverse effects caused by acute or cumulative toxicity in a significant percentage of patients&#41;<br><span class="elsevierStyleHsp" style=""></span>Patients with intolerance to systemic treatment &#40;onset of toxicity or adverse effects at efficacious doses&#41; or a high risk &#40;owing to dose or duration of treatment&#44; individual susceptibility&#44; individual risk factors &#91;age&#44; sex&#44; comorbidities&#44; or potential drug interactions&#93;&#41; of cumulative toxicity with methotrexate&#44; ciclosporin&#44; acitretin&#44; or photo&#40;chemo&#41;therapy&#44; even in the absence of abnormal laboratory results<br><span class="elsevierStyleHsp" style=""></span>Patients&#44; who for reasons of their occupation&#44; timetable and travel limitations&#44; or availability cannot receive treatment with photo&#40;chemo&#41;therapy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1838873.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Source&#58; Puig et al&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">5</span></a></p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Recommendations&#58; Eligibility Criteria for Treatment With Biologics<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a></p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:13 [
            0 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prevalencia de la psoriasis en Espa&#241;a en la era de los agentes biol&#243;gicos"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "C&#46; Ferr&#225;ndiz"
                            1 => "J&#46;M&#46; Carrascosa"
                            2 => "M&#46; Toro"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2013.12.008"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr&#46;"
                        "fecha" => "2014"
                        "volumen" => "105"
                        "paginaInicial" => "504"
                        "paginaFinal" => "509"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24569109"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Physician perspectives in the management of psoriasis and psoriatic arthritis&#58; Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46;C&#46; Van de Kerkhof"
                            1 => "K&#46; Reich"
                            2 => "A&#46; Kavanaugh"
                            3 => "H&#46; Bachelez"
                            4 => "J&#46; Barker"
                            5 => "G&#46; Girolomoni"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.13150"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2015"
                        "volumen" => "29"
                        "paginaInicial" => "2002"
                        "paginaFinal" => "2010"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25885420"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Patient perspectives in the management of psoriasis&#58; Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;G&#46; Lebwohl"
                            1 => "H&#46; Bachelez"
                            2 => "J&#46; Barker"
                            3 => "G&#46; Girolomoni"
                            4 => "A&#46; Kavanaugh"
                            5 => "R&#46;F&#46; Langley"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2013.12.018"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2014"
                        "volumen" => "70"
                        "paginaInicial" => "871"
                        "paginaFinal" => "881"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24576585"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of moderate-to-severe psoriasis in clinical practice&#58; A survey of Spanish dermatologists"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "D&#46; Moreno-Ram&#237;rez"
                            1 => "E&#46; Fonseca"
                            2 => "P&#46; Herranz"
                            3 => "M&#46; Ara"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr&#46;"
                        "fecha" => "2010"
                        "volumen" => "101"
                        "paginaInicial" => "858"
                        "paginaFinal" => "865"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21159262"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Directrices espa&#241;olas basadas en la evidencia para el tratamiento de la psoriasis con agentes biol&#243;gicos&#44; 2013&#46; I&#46; Consideraciones de eficacia y selecci&#243;n del tratamiento"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Puig"
                            1 => "J&#46;M&#46; Carrascosa"
                            2 => "G&#46; Carretero"
                            3 => "P&#46; De la Cueva"
                            4 => "R&#46;F&#46; Lafuente Urrez"
                            5 => "I&#46; Belinchon"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.adengl.2013.04.013"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr&#46;"
                        "fecha" => "2013"
                        "volumen" => "104"
                        "paginaInicial" => "694"
                        "paginaFinal" => "709"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24018211"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly&#58; An observational study from national BIOBADADERM registry"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Medina"
                            1 => "G&#46; Carretero"
                            2 => "C&#46; Ferr&#225;ndiz"
                            3 => "E&#46; Dauden"
                            4 => "F&#46; Vanaclocha"
                            5 => "F&#46;J&#46; G&#243;mez-Garc&#237;a"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.12688"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2015"
                        "volumen" => "29"
                        "paginaInicial" => "858"
                        "paginaFinal" => "864"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25185962"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Biologics for psoriasis&#58; Current evidence and future use"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "C&#46;E&#46; Griffiths"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2012.11207.x"
                      "Revista" => array:7 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2012"
                        "volumen" => "167"
                        "numero" => "Suppl 3"
                        "paginaInicial" => "1"
                        "paginaFinal" => "2"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23082809"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "R&#46; Gniadecki"
                            1 => "B&#46; Bang"
                            2 => "L&#46;E&#46; Bryld"
                            3 => "L&#46; Iversen"
                            4 => "S&#46; Lasthein"
                            5 => "L&#46; Skov"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.13343"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2015"
                        "volumen" => "172"
                        "paginaInicial" => "244"
                        "paginaFinal" => "252"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25132294"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "&#8217;Happy&#8217; drug survival of adalimumab&#44; etanercept and ustekinumab in psoriasis in daily practice care&#58; Results from the BioCAPTURE network"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;M&#46; Van den Reek"
                            1 => "J&#46; Zweegers"
                            2 => "W&#46; Kievit"
                            3 => "M&#46;E&#46; Otero"
                            4 => "P&#46;P&#46;M&#46; Van L&#252;mig"
                            5 => "R&#46;J&#46;B&#46; Driessen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.13087"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2014"
                        "volumen" => "171"
                        "paginaInicial" => "1189"
                        "paginaFinal" => "1196"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24807471"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The evidence for early intervention"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "M&#46;A&#46; Quinn"
                            1 => "S&#46; Cos"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rheum Dis Clin North Am&#46;"
                        "fecha" => "2005"
                        "volumen" => "3"
                        "paginaInicial" => "575"
                        "paginaFinal" => "589"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;M&#46; Van der Kooij"
                            1 => "S&#46; le Cessie"
                            2 => "Y&#46;P&#46; Goekoop-Ruiterman"
                            3 => "J&#46;K&#46; de Vries-Bouwstra"
                            4 => "D&#46; van Zeben"
                            5 => "P&#46;J&#46;S&#46;M&#46; Kerstens"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2008.093294"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis&#46;"
                        "fecha" => "2009"
                        "volumen" => "68"
                        "paginaInicial" => "1153"
                        "paginaFinal" => "1158"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18930988"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Rheumatoid arthritis classificacion criteria&#58; Moving with the times"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "M&#46;A&#46; Quinn"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3899/jrheum.121000"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Rheumatol&#46;"
                        "fecha" => "2012"
                        "volumen" => "39"
                        "paginaInicial" => "2062"
                        "paginaFinal" => "2063"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23118277"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice&#58; 2008-2013 results of the Biobadaderm registry"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "BIOBADADERM Study Group"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Carretero"
                            1 => "C&#46; Ferrandiz"
                            2 => "E&#46; Daud&#233;n"
                            3 => "S&#46;F&#46; Vanaclocha"
                            4 => "F&#46;J&#46; G&#243;mez-Garc&#237;a"
                            5 => "E&#46; Herrera-Ceballos"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.12492"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2015"
                        "volumen" => "29"
                        "paginaInicial" => "156"
                        "paginaFinal" => "163"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24684267"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0039606015002603"
                          "estado" => "S300"
                          "issn" => "00396060"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/15782190/0000010900000007/v1_201809020417/S1578219018302269/v1_201809020417/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6155"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Original Articles"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010900000007/v1_201809020417/S1578219018302269/v1_201809020417/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018302269?idApp=UINPBA000044"
]